These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 23312829

  • 21. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
    Wang W, Guo H, Shi B, Sun H, Li H, Zhang Y, Cai Y.
    Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Everolimus for cardiac rhabdomyomas in children with tuberous sclerosis. The ORACLE study protocol (everOlimus for caRdiac rhAbdomyomas in tuberous sCLErosis): a randomised, multicentre, placebo-controlled, double-blind phase II trial.
    Stelmaszewski EV, Parente DB, Farina A, Stein A, Gutierrez A, Raquelo-Menegassio AF, Manterola C, de Sousa CF, Victor C, Maki D, Morón EM, de Abrantes FF, Iqbal F, Camacho-Vilchez J, Jimenez-Pavón J, Polania JP, Thompson L, Bonanato L, Diebold M, Da Silva MVCP, Nashwan MWJ, Galvani MAG, Idris OEA, Danos P, Ortiz-Lopez R, Mahmoud RAA, Gresse S, Loss KL.
    Cardiol Young; 2020 Mar; 30(3):337-345. PubMed ID: 31983379
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D.
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Effects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: A preliminary report.
    Tsai JD, Wei CC, Yang SH, Fan HC, Hsu CC, Tung MC, Tsai ML, Sheu JN.
    Nephrology (Carlton); 2017 Dec; 22(12):1017-1022. PubMed ID: 27565896
    [Abstract] [Full Text] [Related]

  • 31. Sequential everolimus for angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study.
    Gu L, Peng C, Zhang F, Fang C, Guo G.
    Orphanet J Rare Dis; 2021 Jun 14; 16(1):277. PubMed ID: 34127034
    [Abstract] [Full Text] [Related]

  • 32. The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial.
    Amin S, Mallick AA, Edwards H, Cortina-Borja M, Laugharne M, Likeman M, O'Callaghan FJK.
    EClinicalMedicine; 2021 Feb 14; 32():100715. PubMed ID: 33681737
    [Abstract] [Full Text] [Related]

  • 33. Lymphangioleiomyomatosis.
    Johnson SR, Taveira-DaSilva AM, Moss J.
    Clin Chest Med; 2016 Sep 14; 37(3):389-403. PubMed ID: 27514586
    [Abstract] [Full Text] [Related]

  • 34. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.
    Kingswood JC, Bissler JJ, Budde K, Hulbert J, Guay-Woodford L, Sampson JR, Sauter M, Cox J, Patel U, Elmslie F, Anderson C, Zonnenberg BA.
    Nephron; 2016 Sep 14; 134(2):51-58. PubMed ID: 27504842
    [Abstract] [Full Text] [Related]

  • 35. Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China.
    Luo C, Zhang YS, Zhang MX, Chen MF, Li Y, Qi L, Li HZ, Zu XB, Cai Y.
    Orphanet J Rare Dis; 2021 Jul 03; 16(1):299. PubMed ID: 34217357
    [Abstract] [Full Text] [Related]

  • 36. [Rapamycin in the treatment of renal diseases associated with tuberous sclerosis complex].
    Dun S, Zou LP, Zhang MN, Wang YY, He W, Chen HM, Hu LY, Chen XQ, Lu Q, Pang LY, Liu LY, Tang LN, Wang B.
    Zhonghua Er Ke Za Zhi; 2019 Nov 02; 57(11):852-856. PubMed ID: 31665839
    [Abstract] [Full Text] [Related]

  • 37. Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial.
    Cabrera-López C, Martí T, Catalá V, Torres F, Mateu S, Ballarín J, Torra R.
    Orphanet J Rare Dis; 2012 Nov 11; 7():87. PubMed ID: 23140536
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of low-dose everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex.
    Hatano T, Endo K, Tamari M.
    Int J Clin Oncol; 2021 Jan 11; 26(1):163-168. PubMed ID: 32990779
    [Abstract] [Full Text] [Related]

  • 39. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
    Coombs EJ.
    J Am Assoc Nurse Pract; 2013 Nov 11; 25(11):588-96. PubMed ID: 24170533
    [Abstract] [Full Text] [Related]

  • 40. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
    Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME, RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group.
    Lancet; 2016 Mar 05; 387(10022):968-977. PubMed ID: 26703889
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.